APGE · As filed with the SEC
Apogee Therapeutics income statement, by fiscal year
The statement as Apogee Therapeutics presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
CONSOLIDATED STATEMENT OF OPERATIONS · USD
| USD | FY2025 Year ended Dec 31, 2025 | FY2024 Year ended Dec 31, 2024 | FY2023 Year ended Dec 31, 2023 |
|---|---|---|---|
| Operating expenses: | |||
| Research and development | 214,712,000 | 167,865,000 | 68,424,000 |
| General and administrative | 70,883,000 | 49,005,000 | 24,579,000 |
| Total operating expenses | 285,595,000 | 216,870,000 | 93,003,000 |
| Loss from operations | (285,595,000) | (216,870,000) | (93,003,000) |
| Other income, net: | |||
| Interest income, net | 30,030,000 | 34,742,000 | 9,018,000 |
| Total other income, net | 30,030,000 | 34,742,000 | 9,018,000 |
| Net loss before taxes | (255,565,000) | (182,128,000) | — |
| Provision for income taxes | (278,000) | (18,000) | — |
| Net loss after taxes | (255,843,000) | (182,146,000) | (83,985,000) |
| Net loss per share, basic | (4.22) | (3.3) | (3.36) |
| Net loss per share, diluted | (4.22) | (3.3) | (3.36) |
| Weighted-average common shares outstanding, basic | 60,690,820 | 55,193,971 | 25,005,774 |
| Weighted-average common shares outstanding, diluted | 60,690,820 | 55,193,971 | 25,005,774 |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.